-
1.发明申请公开(公告)号：US20130259883A1
公开(公告)日：2013-10-03
申请号：US13699563
申请日：2011-05-24
申请人： Donald F. Hunt , Jeffrey Shabanowitz , Jennifer Cottine , Ann M. English , Andrew Norris , Victor H. Engelhard , Mark Cobbold , Kara L. Cummings , Angela Zarling , Rebecca C. Obeng , Jie Qian
发明人： Donald F. Hunt , Jeffrey Shabanowitz , Jennifer Cottine , Ann M. English , Andrew Norris , Victor H. Engelhard , Mark Cobbold , Kara L. Cummings , Angela Zarling , Rebecca C. Obeng , Jie Qian
CPC分类号： C07K7/06 , A61K38/00 , A61K39/0011 , C07K7/08 , C07K14/70539 , C07K16/18 , G01N33/5743 , G01N33/57492 , G01N33/6893 , G01N2333/70539 , G01N2440/14
摘要： A set of phosphorylated peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease. Phosphorylated peptides are also presented for other cancers.
摘要翻译： 一组磷酸化肽由黑素瘤细胞表面上的HLA A * 0101，A * 0201，A * 0301，B * 4402，B * 2705，B * 1402和B * 0702呈现。 它们有可能（a）刺激对癌症的免疫应答，（b）在过继性T细胞治疗或疫苗中起到免疫治疗的作用，（c）促进外科病理样本中肿瘤边界的抗体识别， 和（d）作为早期检测疾病的生物标志物。 磷酸化肽也可用于其他癌症。
-
公开(公告)号：US09279011B2
公开(公告)日：2016-03-08
申请号：US13318821
申请日：2010-05-04
申请人： Suzanne L. Topalian , Florence A Depontieu , Donald F. Hunt , Jeffrey Shabanowitz , Jie Qian , Victor H. Engelhard , Angela Lee Zarling
发明人： Suzanne L. Topalian , Florence A Depontieu , Donald F. Hunt , Jeffrey Shabanowitz , Jie Qian , Victor H. Engelhard , Angela Lee Zarling
CPC分类号： C07K14/4748 , A61K39/0011 , A61K39/39 , A61K2039/5154 , A61K2039/5158 , G01N33/5743
摘要： We characterized a total of 175 HLA-DR-associated phosphopeptides using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing and comparative analysis. Many were derived from source proteins which may have roles in cancer development, growth and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome “fingerprints”. We generated HLA-DRβ1*0101-restricted CD4+ T cells specific for a phospho-MART-1 peptide identified in two melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen presenting cells as well as for intact melanoma cells. MHC II-restricted phosphopeptides recognizable by human CD4+ T cells are potential targets for cancer immunotherapy.
摘要翻译： 我们使用顺序亲和分离，生物化学富集，质谱测序和比较分析鉴定了总共175个HLA-DR相关磷酸肽。 许多来源于可能在癌症发展，生长和转移中起作用的源蛋白质。 大多数仅由黑素瘤或转化的B细胞表达，表明定义细胞类型特异性磷酸酯“指纹”的潜力。 我们产生HLA-DR和bgr。1 * 0101限制性CD4 + T细胞，特异于在两个黑素瘤细胞系中鉴定的磷酸化MART-1肽。 这些T细胞对磷酸肽脉冲的抗原呈递细胞以及完整的黑素瘤细胞显示出特异性。 人CD4 + T细胞可识别的MHC II限制性磷酸肽是癌症免疫治疗的潜在靶标。
-
3.发明授权Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor 失效由黑素瘤特异性A1-，A2-和A3-限制性细胞毒性淋巴细胞识别的肽及其用途公开(公告)号：US07019112B1
公开(公告)日：2006-03-28
申请号：US08816454
申请日：1997-03-12
申请人： Craig L. Slingluff , Donald F. Hunt , Jeffrey Shabanowitz , Andrea L. Cox , Victor H. Engelhard , David Kittlesen , Jonathan Skipper , Ronald C. Hendrikson
发明人： Craig L. Slingluff , Donald F. Hunt , Jeffrey Shabanowitz , Andrea L. Cox , Victor H. Engelhard , David Kittlesen , Jonathan Skipper , Ronald C. Hendrikson
IPC分类号： C07K7/06
摘要： Melanoma-specific, A1- and A3-restricted CTL epitopes have been identified in tyrosinase and pMel-17, respectively, and may be used in the design of vaccines.
摘要翻译： 已经在酪氨酸酶和pMel-17中鉴定了黑素瘤特异性，A1-和A3限制性CTL表位，并且可以用于疫苗的设计。
-
公开(公告)号：US20080206268A1
公开(公告)日：2008-08-28
申请号：US11708723
申请日：2007-02-20
CPC分类号： C07K14/70539 , A61K39/00 , A61K2039/5154 , C07K7/06
摘要： Peptide sequences constituting T-cell epitopes of minor Histocompatibility antigen, HA-1. HA-1 is associated with Graft versus Host Disease. The peptides and their derivatives find many uses, for instance, in bone marrow transplantation, organ transplantation and in treatment of leukemia and non-hematopoietic tumors. The peptide and/or its derivatives can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. HA-1 is expressed by non-hematopoietic tumor cells. While absent in normal epithelial cells, tumor cells and tumor cell lines, particularly from epithelial origin, express HA-1 and are recognized by HA-1 cytotoxic T-cells. The invention provides means and methods for HA-1 specific immunotherapy for HA-1-positive patients with non-hematopoietic tumor cells.
摘要翻译： 构成次要组织相容性抗原（HA-1）的T细胞表位的肽序列。 HA-1与移植物抗宿主病有关。 肽及其衍生物在骨髓移植，器官移植和白血病和非造血肿瘤的治疗中发现许多用途。 肽和/或其衍生物可以掺入疫苗中，在药物制剂中，并且它们可以用于诊断测试试剂盒。 HA-1由非造血肿瘤细胞表达。 虽然在正常上皮细胞中不存在，肿瘤细胞和肿瘤细胞系，特别是来自上皮的细胞表达HA-1，并被HA-1细胞毒性T细胞识别。 本发明提供HA-1特异性免疫治疗用于非造血肿瘤细胞的HA-1阳性患者的方法和方法。
-
5.发明授权Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor 有权被A3限制性细胞毒性淋巴细胞识别的半胱氨酸贫化肽，并用于此公开(公告)号：US06558671B1
公开(公告)日：2003-05-06
申请号：US09341982
申请日：1999-09-20
IPC分类号： A61K3900
CPC分类号： C07K14/705 , C12N2799/023
摘要： Cysteine-depleted CTL epitopes can elicit a stronger or more specific CTL response than the native, cysteine-containing CTL epitope of a disease associated antigen.
摘要翻译： 半胱氨酸贫化的CTL表位可以引发比疾病相关抗原的天然含半胱氨酸的CTL表位更强或更特异的CTL应答。
-
公开(公告)号：US07205119B2
公开(公告)日：2007-04-17
申请号：US10791217
申请日：2004-03-02
CPC分类号： C07K14/70539 , A61K39/00 , A61K2039/5154 , C07K7/06
摘要： A peptide sequence of the so-called minor H antigen. The minor H antigens are associated with Graft versus Host disease. The peptide and its derivatives find many uses in bone marrow transplantation, organ transplantation, and in the treatment of leukemia. The peptide and its derivatives can be incorporated into vaccines and pharmaceutical formulations, and they can be used in diagnostic test kits. The peptide is derived from the HA-1 minor antigen, and has the sequence VLXDDLLEA (SEQ ID NO: 1), wherein X represents a histidine or arginine residue. Both donors and recipients in bone marrow transplantation can be treated with the peptides, optionally in combination with other peptides, coupled to carriers, and with suitable excipients and/or adjuvants.
摘要翻译： 所谓的次要H抗原的肽序列。 次要H抗原与移植物抗宿主病有关。 该肽及其衍生物在骨髓移植，器官移植和白血病治疗中有许多用途。 肽及其衍生物可以并入疫苗和药物制剂中，并且它们可以用于诊断测试试剂盒。 该肽衍生自HA-1次要抗原，并具有序列VLXDDLLEA（SEQ ID NO：1），其中X表示组氨酸或精氨酸残基。 骨髓移植中的供体和受体均可用肽处理，任选地与其它肽结合，与载体偶联，并与合适的赋形剂和/或佐剂组合。
-
公开(公告)号：US07008922B2
公开(公告)日：2006-03-07
申请号：US10328927
申请日：2002-12-24
IPC分类号： A61K38/00
CPC分类号： C07K14/705 , A61K38/00 , A61K39/00
摘要： The present invention relates to a peptide which is immunologically recognizable as a T cell epitope of the minor Histocompatibility antigen H-Y. The peptide comprises amino acid sequence SPSVDKARAEL (SEQ ID NO: 1) or FIDSYICQV (SEQ ID NO: 2). The peptide is obtainable from the minor Histocompatibility antigen H-Y. Providing a toxic moiety to the peptide eliminates T cells having specific binding affinity for the peptide. The peptide induces tolerance for transplantations when administered to H-Y-negative recipients.
-
公开(公告)号：US06878375B1
公开(公告)日：2005-04-12
申请号：US09489760
申请日：2000-01-21
IPC分类号： C12N5/10 , A61K35/14 , A61K38/00 , A61K38/17 , A61K39/00 , A61P35/02 , A61P37/06 , C07K7/06 , C07K14/705 , C07K14/74 , C07K16/28 , C12N5/06 , C12Q1/68 , A61K38/04
CPC分类号： C07K14/70539 , A61K39/00 , A61K2039/5154 , C07K7/06
摘要： A peptide sequence of the so-called minor H antigen. The minor H antigens are associated with Graft versus Host disease. The peptide and its derivatives find many uses in bone marrow transplantation, organ transplantation, and in the treatment of leukemia. The peptide and its derivatives can be incorporated into vaccines and pharmaceutical formulations, and they can be used in diagnostic test kits. The peptide is derived from the HA-1 minor antigen, and has the sequence VLXDDLLEA (SEQ. I.D. NO. 1), wherein X represents a histidine or arginine residue. Both donors and recipients in bone marrow transplantation can be treated with the peptides, optionally in combination with other peptides, coupled to carriers, and with suitable excipients and/or adjuvants.
摘要翻译： 所谓的次要H抗原的肽序列。 次要H抗原与移植物抗宿主病有关。 该肽及其衍生物在骨髓移植，器官移植和白血病治疗中有许多用途。 肽及其衍生物可以并入疫苗和药物制剂中，并且它们可以用于诊断测试试剂盒。 肽衍生自HA-1次要抗原，并具有序列VLXDDLLEA（SEQ.ID.NO.1），其中X代表组氨酸或精氨酸残基。 骨髓移植中的供体和受体均可用肽处理，任选地与其它肽结合，与载体偶联，并与合适的赋形剂和/或佐剂组合。
-
公开(公告)号：US06521598B1
公开(公告)日：2003-02-18
申请号：US09000217
申请日：1998-06-26
IPC分类号： A61K3800
CPC分类号： C07K14/705 , A61K38/00 , A61K39/00
摘要： The present invention relates to a peptide which is immunologically recognizable as a T cell epitope of the minor histocompatibility antigen H-Y. The peptide comprises amino acid sequence SPSVDKARAEL (SEQ ID NO:1), or FIDSYICQV (SEQ ID NO:2). The peptide is obtainable from the minor histocompatibility antigen H-Y. Providing a toxic moiety to the peptide eliminates T Cells having specific binding affinity for the peptide. The peptide induces tolerance for transplantations when administered to H-Y-negative recipients.
摘要翻译： 本发明涉及免疫识别为小组织相容性抗原H-Y的T细胞表位的肽。 肽包含氨基酸序列SPSVDKARAEL（SEQ ID NO：1）或FIDSYICQV（SEQ ID NO：2）。 肽可从轻微组织相容性抗原H-Y获得。 向肽提供毒性部分消除对肽具有特异性结合亲和力的T细胞。 当给予H-Y阴性的受体时，该肽诱导了移植的耐受性。
-
公开(公告)号：US5770201A
公开(公告)日：1998-06-23
申请号：US363691
申请日：1994-12-23
CPC分类号： C07K14/70539 , A61K38/00 , A61K39/00 , Y10S530/868
摘要： The present invention discloses the first peptide sequence of a so called minor H antigen, The minor H antigens are associated with the Graft-versus-Host Disease. The peptide and its derivatives find many uses in bone marrow transplantation, organ transplantation and in the treatment of leukemia. The peptide and its derivatives can be incorporated in vaccines, in pharmaceutical formulations and they can be used in diagnostic test kits. The peptide is derived from the HA-2 minor antigen and has the sequence YXGEVXVSV (SEQ ID NO: 1), wherein X represents a leucine or an isoleucine residue. Both donors and recipients in bone marrow transplantation can be treated with the peptides, optionally in combination with other peptides, coupled to carriers, with suitable excipients and/or adjuvants.
摘要翻译： 本发明公开了所谓的小H抗原的第一个肽序列。次要H抗原与移植物抗宿主病有关。 该肽及其衍生物在骨髓移植，器官移植和白血病治疗中有很多用途。 肽及其衍生物可以掺入疫苗，药物制剂中，并可用于诊断试剂盒。 肽衍生自HA-2次要抗原并具有序列YXGEVXVSV（SEQ ID NO：1），其中X表示亮氨酸或异亮氨酸残基。 骨髓移植中的供体和受体都可以用肽治疗，任选地与其它肽结合，与载体偶联，与合适的赋形剂和/或佐剂组合。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.055 秒)
